By Josh Russell
Biosimilar production is an exciting and challenging undertaking for any biopharmaceutical operation. When a patent on a highly effective and valuable biologic expires, a related biologically similar product can be produced, often at a much more accessible price point. Unlike the development of standard generic drugs, biosimilars have a high failure rate during the R&D process and represent a substantial financial investment regardless of success or failure.
The biosimilar market has not been dissuaded by the risk of failure, and it is clear there are remarkable benefits to patient care as these products become more available. The biopharmaceutical industry will continue to find ways to efficiently and effectively produce biosimilar products. Gain further insight into the challenges of biosimilar production, and explore aseptic processing considerations for biosimilars.